Skip to main content Back to Top
Advertisement

9/18/2021

Chloroprocaine Hydrochloride Injection

Products Affected - Description

    • Nesacaine-MPF solution for injection, Fresenius Kabi, 3% (30 mg/mL), 20 mL preservative-free and EDTA-free single dose vial, 25 count, NDC 63323-0478-27

Reason for the Shortage

    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.

Available Products

    • Nesacaine solution for injection, Fresenius Kabi, 1% (10 mg/mL), 30 mL multiple dose vial, 25 count, NDC 63323-0475-37
    • Nesacaine solution for injection, Fresenius Kabi, 2% (20 mg/mL), 30 mL multiple dose vial, 25 count, NDC 63323-0476-37
    • Nesacaine-MPF solution for injection, Fresenius Kabi, 2% (20 mg/mL), 20 mL preservative-free and EDTA-free single dose vial, 25 count, NDC 63323-0477-27
    • Chloroprocaine hydrochloride solution for injection, Hikma, 2% (20 mg/mL), 20 mL preservative-free and EDTA-free single dose vial, 10 count, NDC 00143-9209-10
    • Chloroprocaine hydrochloride solution for injection, Hikma, 3% (30 mg/mL), 20 mL preservative-free and EDTA-free single dose vial, 10 count, NDC 00143-9210-10

Estimated Resupply Dates

    • Fresenius Kabi has Nesacaine-MPF 30 mg/mL 20 mL vials on back order and the company estimates a release date of mid- to late-October 2021.

Updated

Updated September 18, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 15, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.